Integrating New Therapies Into the Management of R/R Myeloma: Experts Address the Paradox of Choice

Join us for this interactive live-stream webinar to learn about planning therapeutic strategies with current and emerging agents for patients with relapsed/refractory multiple myeloma and managing toxicities associated with these novel therapies. This event will offer attendees the opportunity to have their questions answered by the expert faculty.

Not an official event of the 2021 ASCO Annual Meeting. Not sponsored, endorsed, or accredited by ASCO, CancerLinQ, or Conquer Cancer.

To Register: On the Event Dates page click a date/time, click blue Register button in upper right-hand corner. Once registered, you will receive a reminder email with a link to join in advance of the Webinar.


  • Welcome and Introduction
  • Managing Patients with MM After 1st Relapse
  • Treatment Options for Patients with MM After Multiple Relapses
  • Emerging and Investigational Therapies For RR MM
  • Final Thoughts

Each topic will include patient case examples and will conclude with a panel discussion and time for audience questions


Date / Time
Event Details


Paul Richardson, MD

R. J. Corman Professor of Medicine
Harvard Medical School
Clinical Program Leader
Director of Clinical Research

Jerome Lipper Multiple Myeloma Center
Dana-Farber Cancer Institute
Boston, Massachusetts

Nina Shah, MD

Professor of Clinical Medicine
Division of Hematology-Oncology
University of California San Francisco
San Francisco, California

Peter M. Voorhees, MD

Director, Medical Operations and Outreach Services
Department of Hematology/Oncology
Levine Cancer Institute
Charlotte, North Carolina

Goal Statement
The goal of this program is to improve the knowledge and competence of learners in treating patients with relapsed/refractory multiple myeloma.

Target Audience
This educational program is intended for physicians and other healthcare providers who treat patients with relapsed/refractory multiple myeloma.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Plan therapeutic strategies with emerging agents for patients with R/R MM based on available data and individual patient and disease characteristics
  • Explain the mechanism of action of newer classes of agents indicated or under investigation for R/R MM
  • Evaluate the efficacy and safety evidence of novel combination therapeutic regimens for patients with R/R MM
  • Manage toxicities associated with CAR T-cell therapy and BCMA-targeted therapies in patients with R/R MM
  • Identify patients with R/R who would be eligible for enrollment on clinical trials


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation 

CCO designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.